Newsfiscal.ai
Phio Pharmaceuticals to Present Phase 1b Clinical Data at 41st Annual SITC Meeting
· Published
Article summary
Phio Pharmaceuticals announced it will present final clinical data from its Phase 1b trial of PH-762 at the Society for Immunotherapy of Cancer (SITC) annual meeting.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…